Supernus Pharmaceuticals Inc (SUPN)
29.41
+0.53
(+1.84%)
USD |
NASDAQ |
Apr 19, 16:00
29.41
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Cash from Investing (TTM): 268.73M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 268.73M |
| September 30, 2023 | 285.94M |
| June 30, 2023 | 169.08M |
| March 31, 2023 | 93.10M |
| December 31, 2022 | -216.66M |
| September 30, 2022 | -91.77M |
| June 30, 2022 | -15.24M |
| March 31, 2022 | -80.46M |
| December 31, 2021 | -81.91M |
| September 30, 2021 | -108.70M |
| June 30, 2021 | -114.30M |
| March 31, 2021 | -141.58M |
| December 31, 2020 | -34.70M |
| September 30, 2020 | -64.61M |
| June 30, 2020 | -61.66M |
| March 31, 2020 | -19.24M |
| December 31, 2019 | -157.92M |
| September 30, 2019 | -143.03M |
| June 30, 2019 | -109.34M |
| March 31, 2019 | -465.72M |
| December 31, 2018 | -413.48M |
| September 30, 2018 | -466.94M |
| June 30, 2018 | -513.44M |
| March 31, 2018 | -116.66M |
| December 31, 2017 | -86.42M |
| Date | Value |
|---|---|
| September 30, 2017 | -80.93M |
| June 30, 2017 | -70.12M |
| March 31, 2017 | -46.08M |
| December 31, 2016 | -35.96M |
| September 30, 2016 | -35.19M |
| June 30, 2016 | -33.60M |
| March 31, 2016 | -38.82M |
| December 31, 2015 | -39.29M |
| September 30, 2015 | -34.37M |
| June 30, 2015 | -25.09M |
| March 31, 2015 | -12.15M |
| December 31, 2014 | -2.659M |
| September 30, 2014 | 26.20M |
| June 30, 2014 | 30.29M |
| March 31, 2014 | -10.59M |
| December 31, 2013 | -12.11M |
| September 30, 2013 | -42.37M |
| June 30, 2013 | -57.28M |
| March 31, 2013 | -30.56M |
| December 31, 2012 | -48.96M |
| September 30, 2012 | -14.18M |
| June 30, 2012 | 6.463M |
| March 31, 2012 | 18.05M |
| December 31, 2011 | 33.90M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-216.66M
Minimum
Dec 2022
285.94M
Maximum
Sep 2023
-32.86M
Average
-80.46M
Median
Mar 2022
Cash from Investing (TTM) Benchmarks
| Dynavax Technologies Corp | -153.93M |
| Ligand Pharmaceuticals Inc | -11.68M |
| Pacira BioSciences Inc | 77.54M |
| Esperion Therapeutics Inc | 42.50M |
| Collegium Pharmaceutical Inc | -70.81M |